Jade Biosciences, Inc. (JBIO) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Jun 5, 2026
Current Price
$16.08
Price Target
$44.20
Target Range
$34.00 — $55.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-4.0x
Forward PEG—
Implied Growth-18.5%
Median Target$45.00
Analyst Spread47.5%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$34
+111.4%
Consensus
$44
+174.9%
Bull Case
$55
+242.0%
JBIO Price Target Analysis
Updated June 12, 2026As of June 12, 2026, Jade Biosciences, Inc. (JBIO) has a Wall Street consensus price target of $44.20, based on estimates from 4 covering analysts. With the stock currently trading at $16.08, this represents a potential upside of +174.9%. The company has a market capitalization of $525M.
Analyst price targets range from a low of $34.00 to a high of $55.00, representing a 48% spread in expectations. The median target of $45.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, JBIO trades at a trailing P/E of -4.0x. Analysts expect EPS to grow -18.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+47.3%
Avg Forward P/E48.5x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 KRYSKrystal Biotech, Inc. | $9.5B | $321.55 | $326.20 | +1.4% | Buy | 41.5x | 17 |
 RCUSArcus Biosciences, Inc. | $2.3B | $23.30 | $31.17 | +33.8% | Buy | — | 18 |
 IMVTImmunovant, Inc. | $6.8B | $32.88 | $43.67 | +32.8% | Buy | — | 23 |
 ARQTArcutis Biotherapeutics, Inc. | $3.1B | $24.59 | $34.00 | +38.3% | Buy | 123.5x | 12 |
 DAWNDay One Biopharmaceuticals, Inc. | $2.2B | $21.53 | $21.50 | -0.1% | Buy | — | 12 |
 REGNRegeneron Pharmaceuticals, Inc. | $63.5B | $611.48 | $843.84 | +38.0% | Buy | 13.2x | 48 |
 ABBVAbbVie Inc. | $397.6B | $224.77 | $257.54 | +14.6% | Buy | 15.8x | 41 |
 SNDXSyndax Pharmaceuticals, Inc. | $1.6B | $17.91 | $41.00 | +128.9% | Buy | — | 22 |
 PRAXPraxis Precision Medicines, Inc. | $7.2B | $247.98 | $595.93 | +140.3% | Buy | — | 16 |
 KYMRKymera Therapeutics, Inc. | $6.8B | $82.96 | $119.93 | +44.6% | Buy | — | 26 |
Upside Potential Comparison
PRAXSNDXKYMRARQTREGNRCUSIMVTABBVWhat if you invested $1,000 in JBIO 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in JBIO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs JBIO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationJBIO vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowJBIO — Frequently Asked Questions
Quick answers to the most common questions about buying JBIO stock.
What is the JBIO stock price target for 2026?
The consensus Wall Street price target for JBIO is $44.2, representing 174.9% upside from the current price of $16.08. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is JBIO a buy, sell, or hold?
JBIO has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $44.2 implies 174.9% upside from current levels.
Is JBIO stock overvalued or undervalued?
JBIO's current price is $16.08 with a consensus target of $44.2 (174.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can JBIO stock go?
The most bullish Wall Street analyst has a price target of $55 for JBIO, while the most conservative target is $34. The consensus of $44.2 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover JBIO stock?
JBIO is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the JBIO stock forecast?
The 12-month JBIO stock forecast based on 4 Wall Street analysts shows a consensus price target of $44.2, with estimates ranging from $34 (bear case) to $55 (bull case). The median consensus rating is "Buy".
Should I buy JBIO stock?
Wall Street analysts are very optimistic on JBIO, with a "Buy" consensus rating and $44.2 price target (174.9% upside). 4 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do JBIO price targets vary so much?
JBIO analyst price targets range from $34 to $55, a 48% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $44.2 consensus represents the middle ground.